Humanigen

Humanigen, Inc. is a clinical-stage biopharmaceutical company. engages in the development of cell and gene therapies for the treatment of cancers through novel human granulocyte-macrophage colony-stimulating factor neutralization and gene-knockout platforms. The company was founded by Jeng-Horng Her & Robert F. Balint on March 15, 2000 and is headquartered in Essex County, NJ.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Humanigen is a biopharmaceutical company that uses its biologic capabilities and its proprietary platform technology to develop first-in-class human antibody therapeutics. It focuses on preventing the serious and potentially life-threatening side-effects associated with chimeric antigen receptor T-cell (CAR-T) therapy. Its pipeline includes programs such as Lenzilumab, Ifabotuzumab, and HGen005.

The stock price of Humanigen Inc (NASDAQ: HGEN) increased by over 60% pre-market. This is why it happened.

HGEN Stock Price Increased Over 60% Pre-Market: Why It Happened

Humanigen Inc (NASDAQ: HGEN) has reported topline data from Phase 3 study evaluating its lead drug candidate, lenzilumab, in patients hospitalized with COVID-19. The 520-patient study demonstrated that lenzilumab significantly improved patient outcomes.

Humanigen Stock Is Trading Higher As Lenzilumab Improves Survival In Hospitalized COVID-19 Patients

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen announces positive topline results from its Phase 3 clinical trial.

Humanigen Reports Positive Phase 3 Topline Results Demonstrating That Lenzilumab™ Improves Survival Without Need for Mechanical Ventilation in Hospitalized Patients With COVID-19

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm' with its lead drug candidate, lenzilumab, announced that management will host a conference call and webcast today at 8am ET to discuss topline results from the Phase 3 clinical trial of lenzilumab in patients hospitalized with COVID-19. Details for the upcoming conference are below: Webca

Humanigen to Host Conference Call to Report Phase 3 Topline Results of LenzilumabTM in Patients Hospitalized With COVID-19

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. announced today that its board of directors has scheduled the corporation's 2021 Annual Meeting of Shareholders for June 17, 2021.

Humanigen Sets Date for Virtual Annual Shareholders Meeting

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. has obtained a term loan facility from Hercules Capital.

Humanigen Announces $80 Million Loan Facility from Hercules Capital

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. reports financial results for the year ending December 31, 2020 and announces objectives for 2021.

Humanigen Reports Fourth Quarter and Year-End 2020 Financial Results and Provides Corporate Update

Investors need to pay close attention to Humanigen (HGEN) stock based on the movements in the options market lately.

Do Options Traders Know Something About Humanigen (HGEN) Stock We Don't?

Humanigen will release P3 clinical data for Lenzilumab in COVID-19 in late March. We believe that based on the pathophysiology, existing clinical data with GM-CSF blockage and the trial design, the study is more likely to be a success than not.

Humanigen COVID-19 Lenzilumab Trial Is Designed For Success, Data In March

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm' with its lead drug candidate, lenzilumab™, today announced that the Company's management team will participate in a fireside chat at the Roth Conference being held from March 15-17, 2021. An Advance Video Webinar will also be available starting on Monday, March 8, 2021, not March 5, 2021

Humanigen to Present at Roth Conference

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen awarded two patents, expanding their anti-GM-CSF patent portfolio.

Humanigen Expands its anti-GM-CSF Patent Portfolio

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm' with its lead drug candidate, lenzilumab™, today announced that the Company's management team will present and host meetings with investors at the H.C. Wainwright Global Life Sciences Conference being held from March 9-10, 2021, the Roth Conference being held from March 15-17, 2021, and t

Humanigen to Present at Multiple Investor Conferences in March

AIM ImmunoTech Inc

Avid Bioservices

CytoDyn Inc.

Fulgent Genetics

Jaguar Health

PureTech Health PLC

Keep in mind downside risk, if their respective candidates fail to pan out. But, there may be opportunity with these seven biotech stocks targeting treatments for long-haul Covid-19.

7 Biotech Stocks Focused on Chronic Covid Treatment

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm' with its lead drug candidate, lenzilumab™, today announced that the Company's CEO, Cameron Durrant, will participate, present and host meetings with investors and industry colleagues at the BIO CEO & Investor Virtual Conference and the Endpoints Webinars panel, “Repurposing drugs for

Humanigen to Present and Participate at Multiple Upcoming Investor and Industry Conferences

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen announces the election of Dr. Dale Chappell, the Company's chief scientific officer, to serve as a board director of the Company.

Humanigen Elects Dr. Dale Chappell to Board of Directors

BURLINGAME, Calif. & TUSTIN, Calif.--(BUSINESS WIRE)--Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP) (“Avid”) and Humanigen, Inc. (NASDAQ:HGEN) (“Humanigen”) today announced that they have entered into a manufacturing services agreement to expand production capacity for lenzilumab™, Humanigen's therapeutic candidate in development for COVID-19. Lenzilumab is an anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody designed to prevent and treat an immune h

Humanigen and Avid Bioservices Enter Into cGMP Manufacturing Agreement for COVID-19 Therapeutic Candidate Lenzilumab in Support of Potential EUA Filing

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (NASDAQ:HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm with its lead drug candidate lenzilumab™, today announced it has completed enrollment for its pivotal phase 3 study of lenzilumab for COVID-19. The Company expects to announce top-line data in March 2021. The primary objective of this Phase 3 randomized, double-blind, placebo-controlled clin

Humanigen Completes Enrollment in Phase 3 Study of Lenzilumab in Hospitalized Patients with COVID-19

SAN DIEGO & BURLINGAME, Calif.--(BUSINESS WIRE)--Ajinomoto Bio-Pharma Services (“Aji Bio-Pharma”), a leading provider of biopharmaceutical contract development and manufacturing services, and Humanigen, Inc. (NASDAQ:HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm with its lead drug candidate lenzilumab™, today announced the companies will be expanding their manufacturing agreement for the fill fini

Ajinomoto Bio-Pharma Services and Humanigen Expand Manufacturing Agreement to Support Fill Finish for Investigational COVID-19 Therapeutic, Lenzilumab, Nearing Completion of Phase 3 Study

Emergent BioSolutions

Shares of Humanigen Inc. were down 2.5% in trading on Monday after it announced a contract development and manufacturing deal with Emergent BioSolutions Inc. for its experimental COVID-19 treatment. Emergent's stock was down 1.7%.

Humanigen signs manufacturing deal with Emergent for experimental COVID-19 drug

CytoDyn and Humanigen are running high-visibility trials focused on ameliorating COVID-19 acute inflammation. Acute inflammation plays a major role in the hospitalizations and deaths of patients with COVID-19.

CytoDyn And Humanigen: Ticking Time Bombs, Impending Results Likely To Fail

GAITHERSBURG, Md. & BURLINGAME, Calif.--(BUSINESS WIRE)--Emergent BioSolutions Inc. (NYSE:EBS) (Emergent) and Humanigen, Inc. (NASDAQ:HGEN) (Humanigen) today announced that they have entered into a contract development and manufacturing (CDMO) services agreement to accelerate the drug product manufacturing of lenzilumab™, an anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody designed to prevent and treat an immune hyper-response called “cytokine storm.” Eme

Humanigen and Emergent BioSolutions Announce Contract Development and Manufacturing Agreement for Phase 3 COVID-19 Therapeutic Candidate Lenzilumab™

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (NASDAQ:HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm with its lead drug candidate lenzilumab™, today announced an expansion to the Cooperative Research and Development Agreement (CRADA) that the company had previously entered into with the Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear D

Humanigen Announces the Addition of BARDA and Expansion of CRADA with the U.S. Government to Develop Lenzilumab for COVID-19

The company announced an important change to one of its ongoing clinical trials.

Why Humanigen Stock Is Down Today

BURLINGAME, Calif. & CHICAGO--(BUSINESS WIRE)--Humanigen, Inc. (HGEN) (Humanigen), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm with its lead drug candidate lenzilumab™, and EVERSANA, a pioneer of next-generation services to the global life sciences industry, today announced that they are partnering to make lenzilumab available to hospitalized and hypoxic COVID-19 patients in the event that an Emergency Use Authoriz

Humanigen and EVERSANA Announce Partnership to Support the Launch and Commercialization of Lenzilumab for the Treatment of COVID-19

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm' with its lead drug candidate, lenzilumab™, today announced that the Company's management team will present and host meetings with investors and potential partners next week at the H.C. Wainwright BioConnect Conference, J.P. Morgan Healthcare Conference and 23rd Annual ICR Conference being

News for Humanigen Stock (HGEN)